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Knowledge of one’s own HIV status is essential for long-term disease management, but there are few data on how
disclosure of HIV status to infected children and adolescents in sub-Saharan Africa is associated with clinical and
psychosocial health outcomes. We conducted a detailed baseline assessment of the disclosure status, medication
adherence, HIV stigma, depression, emotional and behavioral difficulties, and quality of life among a cohort of Kenyan
children enrolled in an intervention study to promote disclosure of HIV status. Among 285 caregiver–child dyads
enrolled in the study, children’s mean age was 12.3 years. Caregivers were more likely to report that the child knew his/
her diagnosis (41%) compared to self-reported disclosure by children (31%). Caregivers of disclosed children reported
significantly more positive views about disclosure compared to caregivers of non-disclosed children, who expressed
fears of disclosure related to the child being too young to understand (75%), potential psychological trauma for the child
(64%), and stigma and discrimination if the child told others (56%). Overall, the vast majority of children scored within
normal ranges on screenings for behavioral and emotional difficulties, depression, and quality of life, and did not differ
by whether or not the child knew his/her HIV status. A number of factors were associated with a child’s knowledge of
his/her HIV diagnosis in multivariate regression, including older age (OR 1.8, 95% CI 1.5–2.1), better WHO disease
stage (OR 2.5, 95% CI 1.4–4.4), and fewer reported caregiver-level adherence barriers (OR 1.9, 95% CI 1.1–3.4). While
a minority of children in this cohort knew their HIV status and caregivers reported significant barriers to disclosure
including fears about negative emotional impacts, we found that disclosure was not associated with worse psychosocial
outcomes.
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Introduction
There are approximately 3.2 million HIV-infected chil-
dren under the age of 15 worldwide with over 90%
living in sub-Saharan Africa (World Health Organization
[WHO], 2014). With the development of highly active
antiretroviral therapies (HAART), HIV-infected children
can survive well into adolescence and adulthood (WHO,
2011a). A critical component of children’s transition into
these new life periods is learning their HIV status (often
known as “disclosure”), which is required to move into
adult care settings and to take increasing responsibility
for their disease management (Wiener, Mellins, Mar-
hefka, & Battles, 2007). Recommendations for disclos-
ure of HIV status to infected children advocate for a
process of increasing information about HIV and their
serostatus based on cognitive and emotional maturity
(USAID, 2010; WHO, 2011b). A recent review of the
literature on disclosure of HIV status to children found
that children in low- and middle-income countries
(LMIC) are less likely to know their status and to learn
it at later ages compared to children from high-income
countries (Pinzon-Iregui, Beck-Sague, & Malow, 2013).
It is unclear why disclosure happens less often and at
later ages for children in LMIC and factors associated
with a child being more or less likely to know their HIV
status are not well described, particularly in LMIC
(Vreeman, Gramelspacher, Gisore, Scanlon, & Nyan-
diko, 2013). Previous qualitative work in this setting
suggests that caregiver-level fears about the psycholo-
gical impacts of disclosure on children hinder disclosure
efforts but that caregivers also believe that disclosure
may be beneficial in other ways such as improving
adherence to treatment (Vreeman et al., 2009, 2010). A
better understanding of how both child and caregiver-
level factors operate as facilitators and barriers of HIV
disclosure to children are essential to inform guidelines
and interventions to better support children, caregivers,
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and their health care providers. This manuscript provides
a detailed description of baseline disclosure status,
clinical characteristics, medication adherence, HIV-
related stigma, depression, emotional and behavioral
difficulties, quality of life, and school achievement
from a cohort of Kenyan children enrolled in an
intervention study to promote disclosure of HIV status.
Methods
Study design
We conducted a cross-sectional study among a cohort of
Kenyan children and their caregivers enrolled in an
ongoing study to evaluate the effectiveness of a cultur-
ally adapted, multi-component intervention to support
disclosure of HIV status to infected children. Children
and their caregivers are being followed for two years,
with intensive clinical and psychosocial assessments
conducted at baseline and at six-month intervals there-
after. In addition to patient assessments, all participants
are issued Medication Event Monitoring Systems
(MEMS®, MWV/AARDEX Inc.) for electronic dose
monitoring of HAART. This study was approved by the
Institutional Review Board at Indiana University School
of Medicine in Indianapolis, Indiana, USA and by the
Institutional Research Ethics Committee at Moi Univer-
sity School of Medicine in Eldoret, Kenya.
Setting and population
This study is being conducted at eight health facilities of
the Academic Model Providing Access to Healthcare
(AMPATH) – a large HIV treatment program in western
Kenya (Einterz et al., 2007; Inui et al., 2007). Disclosure
protocols at AMPATH recommend initiating disclosure
to children at the age of 10 and implementing full
disclosure before the age of 14 when children are
transferred to adult care. AMPATH clinical staff undergo
annual training on disclosure of HIV status to children,
including training on various strategies to initiate the
disclosure process for of-age children and disclosure
counseling; however, a formal review of how and if
these protocols are being implemented appropriately has
not been conducted. There are not counselors at
AMPATH clinics with dedicated time to assist with or
perform disclosure. The impact of having these counse-
lors in place is a major component of the disclosure
intervention being tested.
Convenience sampling was employed to recruit 35
children at each of the eight facilities from March 2013
to September 2013. Random sampling was not feasible
due to the small number of children in the target age
group at each facility. Eligibility criteria for children
were: being 10–14 years of age, HIV-infected, and on
first-line or second-line HAART. The child’s disclosure
status was not considered for enrollment. There were no
exclusion criteria for caregivers, as long as they reported
being involved in the child’s medical care. Children and
their caregivers were referred to the study team by
clinical staff (nurses and clinicians) or self-referred to the
study team through study fliers placed in participating
health facilities.
Measures
At baseline, each participant was administered a set of
questionnaires by trained study staff. Questionnaires
were administered in the same order for all participants
and were given in Swahili or English depending on the
participant’s preference. Participants’ answers were
recorded on a paper form, which was then entered into
a REDCap database (Harris et al., 2009). Demographic
and clinical characteristics were extracted from the
child’s medical file using a standardized paper clinical
extraction tool and entered into REDCap. WHO disease
stage was defined as worst-ever reported disease stage.
Disclosure questionnaire
A disclosure questionnaire was administered separately
to all children and caregivers. The questionnaire was
developed in this setting through previous qualitative
work (Vreeman et al., 2010). Questionnaire items
included the child’s disclosure status, as well as ques-
tions about the disclosure process, preferences, and fears,
with variations in the child and caregiver questionnaire
versions. All children and caregivers completed the
disclosure questionnaires, with children who indicated
they knew their HIV status answering additional ques-
tions about the disclosure process and preferences. Study
personnel were specifically trained to assess a child’s
disclosure status through multiple strategies, including
speaking with the child, caregiver, and other clinical staff
to protect against inadvertent disclosure. A child was
only considered “disclosed” and asked additional ques-
tions that referred to HIV if the study personnel had
received confirmation of disclosure from the child and
their caregiver.
Adherence questionnaire
The adherence questionnaire was developed and vali-
dated in this setting through previous qualitative and
quantitative work and included questions about missed
doses, barriers to adherence, and medication taking
behaviors (Vreeman, Nyandiko, Ayaya, Walumbe, &
Inui, 2014; Vreeman, Nyandiko, Liu, et al., 2014;
Vreeman, Wiehe, Pearce, & Nyandiko, 2008; Vreeman
et al., 2009). The adherence questionnaire was adminis-
tered either to the child only (when the child and
caregiver reported the child had full responsibility for
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medication taking), the caregiver only (when the child
and caregiver reported the caregiver had full responsib-
ility), or both the child and caregiver (if there was shared
responsibility). An overall adherence variable was not
created for this analysis; each adherence questionnaire
item was individually assessed in univariate analysis for
its association with disclosure status. Adherence vari-
ables can be found in Table 1.
Stigma questionnaire
A 17-item stigma questionnaire was administered to all
caregivers, which asked caregivers to agree or disagree
with a number of statements about their and their child’s
experiences with HIV stigma. The questionnaire was
developed by investigators in this setting and informed
by literature reviews conducted by other investigators
(Earnshaw & Chaudoir, 2009; Steward et al., 2008). A
10-item stigma questionnaire was administered to chil-
dren who indicated they knew their HIV status, as
questions implied HIV infection. Raw scores were
computed for stigma questionnaires with a higher score
indicating higher levels of stigma.
Pediatric AIDS Clinical Trials Group (PACTG) General
Health Assessment for Children (GHAC) Quality of Life
(QoL) Questionnaire
All caregivers completed the multi-domain PACTG
GHAC QoL questionnaire (Gortmaker, Lenderkin, &
Table 1. Adherence, stigma, and psychosocial correlates of disclosure status.
Mean (standard deviation) or frequency count (%)
Variables Overall (n = 285) Non-disclosed (n = 163) Disclosed (n = 122) P value
Adherence variables
Who gives the child medicines
Mother 121 (43%) 76 (47%) 45 (37%) .10
Father 27 (10%) 18 (11%) 9 (7%) .29
Aunt/uncle 30 (11%) 17 (10%) 13 (11%) .95
Grandparent 21 (7%) 12 (7%) 9 (7%) .99
Child takes own 190 (67%) 106 (65%) 84 (69%) .50
Problems taking ART 25 (9%) 14 (9%) 11 (9%) .90
Problems taking ART on time 63 (22%) 39 (24%) 24 (20%) .39
Child-level barriers to taking ART 123 (43%) 77 (47%) 46 (38%) .11
Caregiver-level barriers to taking ART 94 (33%) 63 (39%) 31 (25%) .02
Clinic-level barriers to taking ART 69 (24%) 43 (26%) 26 (21%) .32
Took one or more late doses in the past seven days 82 (29%) 48 (30%) 34 (28%) .70
Missed one or more doses in the past seven days 50 (18%) 31 (20%) 19 (16%) .41
Missed one or more doses in the past 30 days 54 (20%) 29 (18%) 25 (21%) .58
HIV stigma variables
Caregiver stigma score 3.4 (3.3) 3.4 (3.2) 3.5 (3.4) .79
Child stigma score n/a n/a 3.3 (2.1) n/a
GHAC QoL domain scores
General health 78.3 (16.5) 77.8 (16.8) 78.9 (16.1) .59
Physical functioning 88.0 (19.9) 88.4 (18.8) 87.3 (21.3) .64
Psychological well-being 89.1 (10.6) 89.9 (10.5) 88.0 (10.7) .14
Health utilization 99.2 (2.8) 99.3 (2.7) 99.2 (3.0) .74
Health symptoms 89.7 (10.7) 88.4 (11.6) 91.4 (9.2) .02
Strengths and Difficulties Questionnaire
SDQ total difficulties score .93
Normal 260 (92%) 148 (91%) 112 (92%)
Borderline disorder 11 (4%) 6 (4%) 5 (4%)
Abnormal 13 (5%) 8 (5%) 5 (4%)
Patient Health Questionnaire – Depression Screening
PHQ-9 score .57
No depression 227 (81%) 130 (81%) 97 (81%)
Minimal symptoms 41 (15%) 24 (15%) 17 (14%)
Minor depression 7 (3%) 5 (3%) 2 (2%)
Major depression 6 (2%) 2 (1%) 4 (3%)
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Clark, 1998; Lee, Gortmaker, McIntosh, Hughes, &
Oleske, 2006; Lenderking, Testa, Katzenstein, & Ham-
mer, 1997). A raw score was computed as an algebraic
sum for each of the following QoL domains: general
health, physical functioning, psychological well-being,
health utilization, and physical symptoms (Gortmaker
et al., 1998). A higher score indicated a more positive
health outcome, which required reverse coding of some
questionnaire items. Transformation of raw scores to a
0–100 point scale was conducted, as done elsewhere
(Bele, Valsangkar, & Bodhare, 2011; Butler et al., 2009;
Lee et al., 2006). The following formula was used:
Strengths and Difficulties Questionnaire (SDQ) – Youth
Version
All children completed the single-sided SDQ – Youth
Version – a 25-item behavioral screening questionnaire
designed for adolescents aged 11–16 years that asks
about physical and psychological well-being over the
past six months (Goodman, Meltzer, & Bailey, 1998;
Goodman, Renfrew, & Mullick, 2000). The question-
naire is comprised of five domains (of five items each):
emotional problems, conduct problems, hyperactivity,
peer problems, and prosocial. A “total difficulties score”
was calculated using all scales except prosocial, and the
resultant score ranges were from 0–40. A three-band
categorization method was used to classify participants’
score as “normal” (score of 0–15), “borderline” (score of
16–19), and “abnormal” (score of 20–40) as defined
elsewhere (Goodman et al., 1998, 2000).
Patient Health Questionnaire – 9-item depression
instrument (PHQ-9)
All children completed the standard PHQ-9, a 9-item
questionnaire about depression symptoms in the past two
weeks. Raw PHQ-9 scores were calculated and score
ranges were defined as “no depression” (score of 0–4),
“minimal depression” (score of 5–9), “mild major depres-
sion” (score of 10–14), “moderate major depression”
(score of 15–19), and “severe major depression” (score
>20; Kroenke, Spitzer, & Williams, 2001). While
designed for adults, the PHQ-9 has shown good sensitivity
and specificity among adolescents older than 12 years and
among HIV-infected adolescents specifically, although
with a higher optimal cut point for depression (Leahy,
Barton, & Graper, 2012; Richardson et al., 2010).
Missing data
In cases where caregivers or children did not complete
≥1 item in a domain, missing values were computed
using the mean value of non-missing values (Little &
Rubin, 2002). Missing values were rare with no indi-
vidual variable having >2% missing data, and no
participant failed to respond to >2 questions in a domain
or questionnaire.
Analysis
Internal consistency and reliability were assessed using
Cronbach’s alpha (α) where appropriate. Cronbach’s α
was calculated for the stigma questionnaire, QoL, SDQ,
and PHQ-9 (and of individual domains for the QoL and
SDQ). Univariate analysis using Pearson’s chi-square
tests for categorical variables and Student’s t tests for
continuous variables were performed to investigate
demographic, clinical, and psychosocial characteristics
by disclosure status. Disclosure status was defined by
any indication from the caregiver or child that the child
knew his/her HIV status, which was assessed by multiple
questions about the child knowing the name of his/her
illness and why s/he came to clinic or took medicines.
Variables significant in univariate analyses (p < .05)
along with key demographic variables (age, gender, and
orphan status) were included in multivariate logistic
regression. Demographic variables (e.g., age) were
investigated for interactions with clinical, psychosocial,
and adherence variables. All analyses were performed
using SPSS Version 22.0 (IBM Corp, 2013).
Results
Child and caregiver participant characteristics
A total of 285 caregiver–child dyads completed a
baseline evaluation. The mean age of child participants
was 12.3 years (standard deviation: 1.5) and 52% were
female (Table 2). Children had a mean CD4% of 26.4%
(standard deviation: 10.4%) and had been on HAART
for an average of 4.4 years (standard deviation: 2.4). The
majority of caregiver participants were the biological
mother of the child (53%). Only two children (1%) were
not enrolled in school, but 34% of caregivers reported
their child was limited in school because of HIV due to
developmental delays, being held back a grade level, or
not being able to participate in normal school activities
such as sports. At baseline, 43% of children knew their
HIV status per caregiver or child report (i.e., either the
caregiver or the child reported knowing HIV status).
There was significant discordance between caregiver and
child reported disclosure status with 43 caregiver–child
QoL domain score ¼ ðActual score lowest possible scoreÞðHighest possible score lowest possible scoreÞ  100
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dyads (15%) having discordant responses. Caregivers
were more likely to report that the child knew his/her
HIV status (41%) compared to self-reported disclosure
status by children (31%); while 35 caregivers reported
the child knew his/her HIV status and the child reported
not knowing, only eight children reported knowing their
HIV status and the caregiver reported that the child did
not know. Among children who knew their status by
caregiver or child report, caregivers reported a mean age
at disclosure of 10.1 years (range: 6–14).
Caregiver perspectives on disclosure
Caregivers who had already disclosed to their child had
more positive views about disclosure, including the child
and caregiver being more prepared for disclosure and
that the benefits of disclosure outweighed the risks
(Table 3). The most common reasons caregivers of
non-disclosed children gave for not disclosing were that
the child was too young to understand (75%), potential
psychological trauma for the child (64%), and a fear of
stigma and discrimination (56%). These fears were rarely
reported as significant problems by caregivers who had
disclosed. Eighty-two percent of caregivers reported that
disclosure was helpful for the child, including that
disclosure improved adherence to medication (97%)
and the relationship with the caregiver (79%).
Children’s adherence, physical, and psychological
health
Children experienced significant barriers to adherence at
the level of the child (43%), caregiver (33%), and clinic
(24%). Missed doses in the past seven and 30 days were
common with 18% of children reporting a missed dose
in the past seven days and 20% in the past 30 days.
Caregivers reported lower levels of HIV stigma for
themselves and their child (mean stigma score of 3.4
out of 17) compared to children who reported higher
levels of stigma (mean stigma score of 3.3 out of 10).
Table 2. Study participants’ characteristics.
Mean (standard deviation) or frequency count (%)
Variables Overall (n = 285) Non-disclosed (n = 163) Disclosed (n = 122) P valuea
Age (years) 12.3 (1.5) 11.8 (1.3) 13.0 (1.5) <.001
CD4% 26.4 (10.4) 27.4 (9.9) 25.2 (10.9) .08
Duration on antiretroviral therapy (years) 4.4 (2.4) 4.4 (2.3) 4.3 (2.5) .60
Gender (female) 147 (52%) 84 (52%) 63 (52%) .99
Ethnic group .63
Luhya 109 (39%) 57 (36%) 52 (43%)
Kalenjin 76 (27%) 43 (27%) 33 (27%)
Luo 52 (18%) 31 (19%) 21 (17%)
Kikuyu 36 (13%) 24 (15%) 12 (10%)
Other 8 (3%) 5 (3%) 3 (2%)
WHO Stage (using worst reported disease stage) 0.02
1 89 (31%) 47 (29%) 42 (34%)
2 90 (32%) 42 (26%) 48 (39%)
3 93 (33%) 66 (41%) 27 (22%)
4 10 (4%) 6 (4%) 4 (3%)
Orphan status
Both parents dead 141 (50%) 81 (50%) 60 (49%) .85
Mother dead 89 (31%) 55 (34%) 34 (27.9%) .29
Father dead 90 (32%) 54 (33%) 36 (30%) .52
Sibling(s) has HIV 52 (20%) 32 (21%) 20 (18%) .46
Enrolled in school 279 (99%) 159 (99%) 120 (99%) .84
Caregiver at assessment .83
Biological mother 152 (53%) 87 (54%) 65 (53%)
Aunt/uncle 39 (14%) 22 (14%) 17 (14%)
Adoptive parent 30 (11%) 20 (12%) 10 (8%)
Biological father 25 (9%) 15 (9%) 10 (8%)
Grandparent 18 (6%) 9 (6%) 9 (7%)
Sibling 13 (5%) 6 (4%) 7 (6%)
Other 7 (2%) 3 (2%) 4 (3%)
aP values were computed using Student’s t tests for continuous variables and Pearson’s chi-square tests for categorical variables.
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Table 3. Caregivers’ preferences for and experiences of disclosure to children.
Percent of caregivers who agreed with statement
Caregivers who had NOT
disclosed (n = 163)
Caregivers who had
disclosed (n = 122)
P
value
Variables from the Disclosure Questionnaire
My child is/was ready for disclosure 107 (67%) 101 (84%) .002
My child needs/needed to know his/her status 134 (83%) 116 (96%) .001
I feel/felt prepared to tell my child 96 (57%) 107 (90%) <.001
It is/was very important to me that I am the one to tell my child so that
they do not hear about their status from someone else
138 (86%) 109 (91%) .20
I feel/felt supported by my child’s health-care provider to disclose to
the child
134 (84%) 108 (91%) .09
I think/thought the child would be motivated to take their medications if
they knew their diagnosis
125 (79%) 110 (92%) .004
I feel prepared to answer questions that my child might have about his/
her illness
145 (90%) 111 (92%) .63
I worry my child will lose hope or focus on dying because they know
their diagnosis
44 (28%) 20 (16%) .03
I worry about the risk of stigma if my child were to tell others about
his/her diagnosis
51 (32%) 29 (24%) .16
I think the benefits of telling my child about his/her diagnosis
outweighs/outweighed the possible risks
136 (85%) 114 (93%) .02
I was the one who made the decision to disclose to my child n/a 84 (77%) n/a
Variables from the GHAC QoL Infection Status domain
What are your reasons for not telling your child his/her diagnosis: n/a n/a
My child is too young 131 (75%)
I do not want my child to be sad or depressed 112 (64%)
My child could tell people who should not know 98 (56%)
I don’t want my child to be afraid of death 90 (52%)
The family will be less stressed 62 (36%)
My child will be happier not knowing 84 (48%)
I do not want my child left out or discriminated against 97 (56%)
Are any of the following problems because your child does not know
his/her diagnosis:
n/a n/a
My child is unsure why he/she is coming to a special clinic/doctor 113 (65%)
My child knows I am not telling the truth about his/her illness 46 (26%)
My child is less cooperative with medical care or taking medicines 23 (13%)
My child does not know how to be responsible for not infecting others 95 (55%)
My child’s behavior is worse due to not knowing 2 (1%)
How does your child feel about life with his/her medical condition: n/a n/a
Sad 25 (15%)
Content/glad 118 (69%)
Frightened 18 (10%)
In control 108 (63%)
Angry 24 (14%)
Who encouraged you to discuss the diagnosis with your child: n/a n/a
I encouraged it 37 (33%)
Other family members 8 (7%)
Child asking questions 2 (2%)
Health-care provider 68 (61%)
Who participated in the discussion of the child’s diagnosis: n/a n/a
I participated 77 (69%)
Other family members 33 (30%)
Health-care provider 39 (35%)
How did you feel about the discussion of the child’s diagnosis: n/a n/a
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Mean QoL scores indicated high levels of physical and
psychological functioning of children in this cohort, and
few children scored outside the normal range of the SDQ
(4% scored in the “borderline” range and 5% in the
“abnormal” range). Depressive symptoms were more
common, with 15% of children having minimal, 3%
having minor, and 2% having major depressive
symptoms.
Patterns and correlates of disclosure status
In univariate analysis, the child’s older age (p < .001),
better WHO stage (1 or 2 versus 3 or 4; p = .02),
caregiver reporting fewer physical health symptoms
(physical health QoL domain; p = .02), and fewer
caregiver-level adherence barriers (p = .02) were all
significantly associated with the child’s knowledge of
his/her HIV status. Only the child’s older age (OR 1.8,
95% CI 1.5–2.1), better WHO stage (OR 2.5, 95% CI
1.4–4.4), and fewer caregiver-level adherence barriers
(OR 1.9, 95% CI 1.1–3.4) were predictive of disclosure
in multivariate regression analysis (Table 4).
Internal consistency of instruments
The instruments used to evaluate stigma, QoL, beha-
vioral problems, and depression showed moderate to
good levels of internal consistency using Cronbach’s α.
The caregiver stigma questionnaire showed good internal
consistency (Cronbach’s α = .849), as did the QoL
domains with Cronbach’s α on the various domains
ranging from .807 (general health) to .867 (physical
Table 3. (Continued)
Percent of caregivers who agreed with statement
Caregivers who had NOT
disclosed (n = 163)
Caregivers who had
disclosed (n = 122)
P
value
I felt the discussion was helpful for my child 92 (82%)
I felt we had enough support from the health-care team 76 (68%)
I felt my child understood what was explained 71 (63%)
I did not feel my child understood what was explained 3 (3%)
I did not feel the health-care team was helpful enough 6 (5%)
I felt the discussion was too difficult for my child 11 (10%)
I was not present for the discussion 16 (14%)
What has been good about your child knowing his/her diagnosis: n/a n/a
He/she is more cooperative about medical care and taking medicine 107 (97%)
He/she is more open with family and friends 66 (60%)
He/she understands why he/she is sick 101 (92%)
He/she understands responsibility to avoid infecting others 68 (62%)
Telling him/her the truth has improved our relationship 87 (79%)
Are any of the following problems because your child knows his/her
diagnosis:
n/a n/a
My child told friends, neighbors, or others who shouldn’t know 9 (8%)
My child told family members who shouldn’t know 9 (8%)
My child is sad or depressed 5 (5%)
My child is afraid of death 24 (22%)
My child’s behavior is worse 1 (1%)
My child is less cooperative with medical care or taking medicines 15 (14%)
My child has been left out or discriminated against 1 (1%)
When your child was first told his/her diagnosis, was he/she: n/a n/a
Sad 40 (37%)
Content/glad 45 (41%)
Frightened 30 (27%)
Relieved 73 (66%)
Angry 20 (18%)
How does your child feel now about life with his/her medical
condition:
n/a n/a
Sad 9 (8%)
Content/glad 85 (77%)
Frightened 11 (10%)
In control 88 (80%)
Angry 6 (5%)
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symptoms). The PHQ-9 and SDQ showed relatively
good reliability overall (Cronbach’s α = .779 and .746,
respectively); however, SDQ domains performed more
poorly (Cronbach’s α ranged from .259 to .644).
Discussion
We found just over 40% of 10 to 14-year-olds knew their
HIV status by caregiver report, which is similar to a
previous study in this setting (Vreeman, Scanlon, et al.,
2014) and similar to estimates from other LMIC (Vree-
man et al., 2013). Given that more than half of children
over 10 still do not know their status, the current
disclosure protocol in place at AMPATH has clearly
not been effectively implemented. There are likely
several health systems factors that contribute to the
ineffectiveness of the current disclosure protocol, includ-
ing busy caseloads for clinicians that do not allow for
enough time to assess disclosure readiness and conduct
disclosure counseling in routine care and inadequate
training and tools to use for disclosure counseling. Lack
of caregiver readiness and fears about negative child-
level (e.g., psychological distress) and family-level (e.g.,
stigma and discrimination) consequences of disclosure
certainly contribute to a reluctance to disclose, as this
and previous work among Kenyan caregivers suggest
(Vreeman et al., 2010). While there were no differences
in reported missed doses, disclosed children reported
significantly fewer caregiver-level adherence barriers.
While we cannot assess the relationship between dis-
closure and adherence given the cross-sectional nature of
this study, the role that disclosure plays in reducing
adherence barriers at the child and caregiver level has
been supported by previous qualitative work in this
setting (Vreeman et al., 2009, 2010) and others
(Bikaako-Kajura et al., 2006). Using the longitudinal
data we are collecting on disclosure status and adherence
to HAART over two years of follow-up with this cohort,
we will be able to provide more data to investigate the
relationship between disclosure and adherence in the
future.
Overall, children in this cohort demonstrated few
psychosocial health problems and scored in the normal
ranges of screenings for psychological functioning,
behavioral and emotional difficulties, and depression
symptoms, and did not differ by disclosure status. There
are few studies on psychosocial health and QoL among
HIV-infected adolescents in sub-Saharan Africa
(Mabugu, Revill, & van den Berg, 2013). A number of
studies among Kenyan adolescents have found high rates
of depression and anxiety, with one study finding 41% of
adolescents admitted to inpatient and outpatient wards
had indications of mild to moderate depression using the
Children’s Depression Inventory (Ndetei, Khasakhala,
Mutiso, & Mbwayo, 2009; Ndetei et al., 2008), but none
of these studies focused on mental health among HIV-
infected adolescents. A study from the USA among
similarly aged HIV-infected adolescents using the same
GHAC QoL scoring criteria that was used in this study
showed generally high physical and psychological health
functioning that was comparable to what we report
(Butler et al., 2009). Few studies have investigated the
psychological impact of disclosure on adolescents, but
studies like this one and others have not found increased
psychological problems among disclosed children (But-
ler et al., 2009; Mellins et al., 2002) with one study
reporting disclosed children scored lower on depression
and anxiety measures compared to non-disclosed chil-
dren (Riekert, Wiener, & Battles, 1999).
Older children and adolescents have significantly
more AIDS-related mortality compared to younger
children and young adults in LMIC (Porth, Suzuki,
Gillespie, Kasedde, & Idele, 2014). We found that
disclosed children actually had better WHO disease
stage overall, but we did not find significant correlations
between disclosure and CD4%, hospitalizations, and
health utilization. Studies on the association between
disclosure status and clinical outcomes like virologic
outcomes and disease progression have shown conflict-
ing results (Ferris et al., 2007; Mellins et al., 2002;
Sirikum, Sophonphan, Chuanjaroen, Lakonphon, &
Srimuan, 2013). We found that caregivers of disclosed
children reported significantly fewer physical health
symptoms compared to caregivers of non-disclosed
children, which may be due to their less advanced
disease stage. Increased physical symptoms reported by
Table 4. Factors associated with disclosure in multivariate regression.
Variables P value from univariate analysis Odds ratio (95% confidence interval)
Child’s older age (years) <.001 1.8 (1.5–2.1)
WHO stage 1 or 2 versus 3 or 4 .02 2.5 (1.4–4.4)
Fewer caregiver-level adherence barriers .02 1.9 (1.1–3.4)
Fewer caregiver reported physical health symptoms .02 NS
Note: Child gender and orphan status were also included in the multivariate regression model but were not significant in univariate or multivariate
regression analysis.
NS, not significant (i.e., 95% confidence interval included 1) in multivariate regression.
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caregivers of non-disclosed children may also be man-
ifestations of psychosocial or emotional challenges such
as depression or anxiety presenting as general physical
complaints. This is a known phenomenon in children; a
number of studies have found associations between
psychosocial problems in children like depression, anxi-
ety, and behavioral problems and physical symptoms
(Campo, Jansen-McWilliams, Comer, & Kelleher, 1999;
Campo et al., 2004; Dorn et al., 2003; Egger, Costello,
Erkanli, & Angold, 1999; Garber, Zeman, & Walker,
1990; Watson et al., 2003) although there is conflicting
evidence about how common this is (Song et al., 1998;
Walker, Garber, & Greene, 1993; Walker & Greene,
1989). In a setting where expressing mental health
symptoms such as depression or anxiety may not be
culturally acceptable or where cross-cultural perform-
ance of instruments to evaluate emotional and mental
health symptoms may not be adequate, these general
health complaints may reflect additional areas of concern
for non-disclosed children (Simon, VonKorff, Piccinelli,
Fullerton, & Ormel, 1999).
This study has several limitations. First, while we
attempted to use validated, reliable instruments, most
have not been validated in East Africa or in the
adolescent population (Monahan et al., 2009; Omoro,
Fann, Weymuller, Macharia, & Yueh, 2006). This leads
to some uncertainty about whether children are experi-
encing any mental health issues or whether the instru-
ments are performing adequately. Nonetheless, detailed
evaluations of mental, emotional, and behavioral func-
tioning, as well as QoL, are generally lacking for this
population and this manuscript reports a comprehensive
inventory that can be used for future validation work. We
also calculated Cronbach’s α for the instruments and
various domains tested that overall showed good internal
consistency. Second, these data are limited to a cross-
sectional sampling that precludes drawing conclusions
about causation; however, the ongoing study’s longitud-
inal evaluations will allow us to better answer the
important questions about the impact of disclosure over
time. We also used convenience sampling based on
clinical staff referral or self-referral for enrollment; it is
possible that children and their caregivers who agreed to
participate in the study differed in important ways
compared to those who declined participation or did
not self-refer. We did not collect data on subjects who
declined participation as this is often viewed with
suspicion in this clinical population, and thus could not
assess differences among those who declined and agreed
to participate. Third, we did see discrepancies between
caregivers’ and children’s reports of disclosure. This may
be related to the strong mandate to children not to report
their HIV status to anyone, resulting in incorrect
reporting to study personnel. This also might reflect
incomplete disclosure to children, where indirect
communication about HIV or discomfort with open
discussion leads caregivers to think that disclosure has
been carried out when, in fact, children have not grasped
the full understanding of their diagnosis.
Conclusion
As the world’s cohorts of HIV-infected children reach
adolescence, we face a critical need to support youth and
their families through the process of disclosure. This
detailed evaluation of a cohort of HIV-infected Kenyan
children suggests that undergoing disclosure does not
increase their mental, emotional, or behavioral distress.
In contrast, disclosure was tied with a positive outlook
on the part of the involved caregivers. Despite the
potential for positive benefits to informing a child about
their HIV status, a majority of older children and
adolescents still do not know their status and are in
need of disclosure counseling and services. Supporting
families through the child disclosure process and finding
ways to promote child physical and psychosocial health
through this pivotal time of transition should be import-
ant targets for clinical care systems, particularly those in
LMIC where millions of HIV-infected children will be
entering adolescence.
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